New treatment for painful diabetic nerve damage using cannabidiol and palmitoylethanolamide tablets
Cannabidiol/Palmitoylethanolamide sublingual tablets for the treatment of Painful Diabetic Peripheral Neuropathy
This study is testing a new type of tablet that combines two ingredients to help relieve pain for people with painful diabetic peripheral neuropathy, aiming to provide relief without the side effects of regular pain medications.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pure Green Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (West Bloomfield, United States) |
| Project ID | NIH-10932267 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for painful diabetic peripheral neuropathy (pDPN) using sublingual tablets that combine cannabidiol and palmitoylethanolamide. The approach aims to provide effective pain relief by targeting multiple pain pathways without the adverse effects commonly associated with traditional pain medications. Patients will take these tablets under supervision to assess their effectiveness and safety in alleviating symptoms of pDPN. The study seeks to fill a significant gap in treatment options for this debilitating condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with painful diabetic peripheral neuropathy who are seeking alternative pain relief options.
Not a fit: Patients who do not have diabetic peripheral neuropathy or those who are not diabetic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a safer and more effective pain management option for patients suffering from painful diabetic peripheral neuropathy.
How similar studies have performed: While there have been limited advancements in neuropathic pain treatments, this specific combination of cannabidiol and palmitoylethanolamide represents a novel approach that has not been widely tested in clinical settings.
Where this research is happening
West Bloomfield, United States
- Pure Green Pharmaceuticals, INC. — West Bloomfield, United States (Active)
Researchers
- Principal investigator: Kimless, Debra — Pure Green Pharmaceuticals, INC.
- Study coordinator: Kimless, Debra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.